10-Q quarterly report · filed Oct 29, 2026

Incyte (INCY) Q3 2026 10-Q Quarterly Report

Short answer

Incyte (INCY) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.6B (up 14.0% year over year) with net income of −$785M.

Q3 2026 key financials · XBRL

Revenue
$1.6B
+14.0% YoY · −7.0% QoQ
Net income
−$785M
−285.0% YoY · −234.0% QoQ
Operating margin
-45.5%
EPS (diluted)
−$3.78
−279.1% YoY · −234.5% QoQ

Source: XBRL data from the Incyte (INCY) Q3 2026 10-Q on SEC EDGAR. USD.

Incyte Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Total revenue $1,557.2M, up $191.2M YoY from $1,366.0M
  • Net loss $784.8M vs net income $424.2M YoY, driven by $1.23B Vega IPR&D expense
  • Best product OPZELURA, sales $254.9M vs $188.0M; worst ICLUSIG, $33.5M vs $37.6M
  • Cash, equivalents and marketable securities $3.9B; operating cash flow $201.7M vs $870.2M YoY
  • Outlook: cash resources adequate for foreseeable future; FDA povorcitinib decision anticipated first quarter 2027

Risk Factors

  • Newly added acquisition risk: July 2026 Vega Therapeutics acquisition creates integration, compliance and contingent-liability exposure
  • Most material patent risk: Generic JAKAFI manufacturers’ challenges remain pending against patents expiring December 2028
  • Regulatory risk: Inflation Reduction Act manufacturer discount obligations increase as Medicare Part D provisions phase out
  • Near-term commercial risk: OPZELURA generic challenges remain pending against patents expiring in 2031 and 2040
  • Financial risk: Global operations expose revenues and net income to unfavorable foreign-currency fluctuations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Incyte quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.